SCHEMBL16633352

SCHEMBL16633352

CCOC(=O)C(N)c1ccc(OC(F)(F)F)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.52
PPARG P37231 2/20 0.46
PPARA Q07869 2/20 0.46
EPHX2 P34913 2/20 0.46
ALDH1A1 P00352 2/20 0.44
PDE2A O00408 3/20 0.44
EPHX1 P07099 2/20 0.43
PPARD Q03181 1/20 0.43
HRH2 P25021 1/20 0.42
HRH1 P35367 1/20 0.42
SLC5A1 P13866 1/20 0.41
SLC5A2 P31639 1/20 0.41
HRH3 Q9Y5N1 1/20 0.41
LMNA P02545 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HDAC3 O15379 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC2 Q92769 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
NOS3 P29474 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15647495 0.84 POLB (0.55) POLBPPARGPPARAEPHX2ALDH1A1
SCHEMBL950460 0.84 ALDH1A1 (0.50) POLBEPHX2ALDH1A1PDE2AEPHX1
SCHEMBL10599023 0.83 KCNH2 (0.44) ALDH1A1LMNA
Hydrochloric Acid SCHEMBL3582167 0.83 ALDH1A1 (0.49) POLBEPHX2ALDH1A1PDE2AEPHX1
SCHEMBL12175577 0.83 POLB (0.54) POLBPPARGPPARAEPHX2ALDH1A1
SCHEMBL21287988 0.83 TRPM8 (0.43) POLBEPHX1L3MBTL1
Hydrochloric Acid SCHEMBL28936698 0.82 TRPM8 (0.42) POLBEPHX1L3MBTL1
Hydrochloric Acid SCHEMBL28936699 0.82 TRPM8 (0.42) POLBEPHX1L3MBTL1
SCHEMBL12175578 0.82 POLB (0.52) POLBPPARGPPARAEPHX2ALDH1A1
SCHEMBL1938686 0.82 POLB (0.52) POLBPPARGPPARAEPHX2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9469637-B2 Nitrogenated heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-10-18 US disclosed
US-20150105373-A1 NITROGENATED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150105373-A1 NITROGENATED HETEROCYCLIC COMPOUND PDE2A, PDE5A, PDE3A POLB 2346/4885PPARG 1437/4885PPARA 1415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.